Table I.
Bioactive Chemerin Concentration in Human Samples
| Sample | Pathology | Chemerin (ng/ml) |
|---|---|---|
| 1 | Ovary Carcinoma | 74 |
| 2 | Ovary Carcinoma | 73 |
| 3 | Ovary Carcinoma | 104 |
| 4 | Ovary Carcinoma | 92 |
| 5 | Ovary Carcinoma | n.d. (<10) |
| 6 | Ovary Carcinoma | 82 |
| 7 | Ovary Carcinoma | 103 |
| 8 | Ovary Carcinoma | 43 |
| 9 | Ovary Carcinoma | 87 |
| 10 | Ovary Carcinoma | n.d. (<10) |
| 11 | Ovary Carcinoma | 90 |
| 12 | Ovary Carcinoma | 33 |
| 13 | Ovary Carcinoma | 57 |
| 14 | Ovary Carcinoma | 87 |
| 15 | Ovary Carcinoma | 62 |
| 16 | Ovary Carcinoma | 37 |
| 17 | O.H.S. | 116 |
| 18 | Arthritis | 358 |
| 19 | Osteoarthritis | n.d. (<1) |
The amount of chemerin in ascitic (samples 1-17) and synovial (samples 18 and 19) fluids was estimated after two fractionation steps, by assaying the fractions on chemerinR-expressing cells using the aequorin-based assay and a standard curve made with purified recombinant human chemerin. Synovial fluids from arthritis and osteoarthritis patients were pooled for measurement after centrifugation. O.H.S., ovarian hyperstimulation syndrome; n.d., not detectable (the limit of detection in the assay conditions is given).